Mutator Mutations Enhance Tumorigenic Efficiency across Fitness Landscapes

por Beckman, Robert A.
Publicado 2009

New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs

por Beckman, Robert A., Chen, Cong
Publicado 2013

Long range personalized cancer treatment strategies incorporating evolutionary dynamics

por Yeang, Chen-Hsiang, Beckman, Robert A.
Publicado 2016

Rare Mutations in Cancer Drug Resistance and Implications for Therapy

por Beckman, Robert A., Loeb, Lawrence A.
Publicado 2020

How Should Cancer Models Be Constructed?

por Beckman, Robert A., Kareva, Irina, Adler, Frederick R.
Publicado 2020

Optimizing Trial Designs for Targeted Therapies

por Ondra, Thomas, Jobjörnsson, Sebastian, Beckman, Robert A., Burman, Carl-Fredrik, König, Franz, Stallard, Nigel, Posch, Martin
Publicado 2016

The National Brain Injury, Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms

por Mozayeni, B. Robert, Duncan, William, Zant, Eddie, Love, Tommy L., Beckman, Robert L., Stoller, Kenneth P.
Publicado 2019

Optimized adaptive enrichment designs

por Ondra, Thomas, Jobjörnsson, Sebastian, Beckman, Robert A, Burman, Carl-Fredrik, König, Franz, Stallard, Nigel, Posch, Martin
Publicado 2017

Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Can...

por Kristof, Jessica, Sakrison, Kellen, Jin, Xiaoping, Nakamaru, Kenji, Schneider, Matthias, Beckman, Robert A, Freeman, Daniel, Spittle, Cindy, Feng, Wenqin
Publicado 2017

Evidence-Based Network Approach to Recommending Targeted Cancer Therapies

por Kancherla, Jayaram, Rao, Shruti, Bhuvaneshwar, Krithika, Riggins, Rebecca B., Beckman, Robert A., Madhavan, Subha, Corrada Bravo, Héctor, Boca, Simina M.
Publicado 2020

Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis

por Tang, Rui (Sammi), Zhu, Jian, Chen, Tai-Tsang, Liu, Fang, Jiang, Xun, Huang, Bo, Lee, J. Jack, Beckman, Robert A.
Publicado 2022

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

por Ghadessi, Mercedeh, Tang, Rui, Zhou, Joey, Liu, Rong, Wang, Chenkun, Toyoizumi, Kiichiro, Mei, Chaoqun, Zhang, Lixia, Deng, C. Q., Beckman, Robert A.
Publicado 2020

Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective

por Ghadessi, Mercedeh, Di, Junrui, Wang, Chenkun, Toyoizumi, Kiichiro, Shao, Nan, Mei, Chaoqun, Demanuele, Charmaine, Tang, Rui (Sammi), McMillan, Gianna, Beckman, Robert A.
Publicado 2023

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment

por Rao, Shruti, Beckman, Robert A., Riazi, Shahla, Yabar, Cinthya S., Boca, Simina M., Marshall, John L., Pishvaian, Michael J., Brody, Jonathan R., Madhavan, Subha
Publicado 2016

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

por Bahnassy, Shaymaa, Stires, Hillary, Jin, Lu, Tam, Stanley, Mobin, Dua, Balachandran, Manasi, Podar, Mircea, McCoy, Matthew D., Beckman, Robert A., Riggins, Rebecca B.
Publicado 2023

A framework for assessing the impact of accelerated approval

por Gould, A. Lawrence, Campbell, Robert K., Loewy, John W., Beckman, Robert A., Dey, Jyotirmoy, Schiel, Anja, Burman, Carl-Fredrik, Zhou, Joey, Antonijevic, Zoran, Miller, Eva R., Tang, Rui
Publicado 2022

Extensive subclonal mutational diversity in human colorectal cancer and its significance

por Loeb, Lawrence A., Kohrn, Brendan F., Loubet-Senear, Kaitlyn J., Dunn, Yasmin J., Ahn, Eun Hyun, O’Sullivan, Jacintha N., Salk, Jesse J., Bronner, Mary P., Beckman, Robert A.
Publicado 2019

Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival

por Roszik, Jason, Lee, J. Jack, Wu, Yi-Hung, Liu, Xi, Kawakami, Masanori, Kurie, Jonathan M., Belouali, Anas, Boca, Simina M., Gupta, Samir, Beckman, Robert A., Madhavan, Subha, Dmitrovsky, Ethan
Publicado 2022

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced...

por Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Publicado 2015

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado 2013